These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15944869)

  • 1. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
    Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
    Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical effect of sibutramine on autonomic cardiovascular regulation.
    Birkenfeld AL; Schroeder C; Boschmann M; Tank J; Franke G; Luft FC; Biaggioni I; Sharma AM; Jordan J
    Circulation; 2002 Nov; 106(19):2459-65. PubMed ID: 12417543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
    Heusser K; Tank J; Diedrich A; Engeli S; Klaua S; Krüger N; Strauss A; Stoffels G; Luft FC; Jordan J
    Clin Pharmacol Ther; 2006 May; 79(5):500-8. PubMed ID: 16678551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
    Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP
    Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
    Jordan J; Scholze J; Matiba B; Wirth A; Hauner H; Sharma AM
    Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
    Faria AN; Ribeiro Filho FF; Lerario DD; Kohlmann N; Ferreira SR; Zanella MT
    Arq Bras Cardiol; 2002 Feb; 78(2):172-80. PubMed ID: 11887193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
    Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG; Egri Z
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.